Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S100B | P04271 | 3/20 | 0.71 |
| ▸ | CA2 | P00918 | 4/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.63 |
| ▸ | MAPT | P10636 | 3/20 | 0.63 |
| ▸ | MEN1 | O00255 | 3/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.63 |
| ▸ | BLM | P54132 | 2/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | THRB | P10828 | 1/20 | 0.63 |
| ▸ | PKM | P14618 | 1/20 | 0.63 |
| ▸ | CASP3 | P42574 | 1/20 | 0.63 |
| ▸ | RECQL | P46063 | 1/20 | 0.63 |
| ▸ | PLEC | Q15149 | 1/20 | 0.63 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.63 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.63 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.63 |
| ▸ | DHODH | Q02127 | 1/20 | 0.62 |
| ▸ | GLA | P06280 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2311083 | 1.00 | S100B (0.71) | S100BCA2ALDH1A1KDM4EL3MBTL1 | |
| 4-(Benzylideneamino)Phenol SCHEMBL1877533 | 0.91 | S100B (0.71) | S100BCA2ALDH1A1KDM4EL3MBTL1 | |
| 4-(Benzylideneamino)Phenol SCHEMBL1877535 | 0.91 | S100B (0.71) | S100BCA2ALDH1A1KDM4EL3MBTL1 | |
| Phenol SCHEMBL3852646 | 0.91 | S100B (0.61) | S100BCA2ALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL15347676 | 0.89 | CA2 (0.71) | S100BCA2ALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL2839684 | 0.89 | CA2 (0.71) | S100BCA2ALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL14373623 | 0.89 | CA2 (0.71) | S100BCA2ALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL11320970 | 0.89 | CA2 (0.71) | S100BCA2ALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL14129042 | 0.89 | ALDH1A1 (0.69) | S100BCA2ALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL59999 | 0.84 | ALDH1A1 (0.63) | S100BCA2ALDH1A1KDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10975307-B2 | Liquid crystalline epoxy compound with terminal mesogen connected by flexible linkage and method for preparing the same | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2021-04-13 | — | — | US | disclosed |
| US-20180201835-A1 | LIQUID CRYSTALLINE EPOXY COMPOUND WITH TERMINAL MESOGEN CONNECTED BY FLEXIBLE LINKAGE AND METHOD FOR PREPARING THE SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2018-07-19 | — | — | US | disclosed |
| US-8766004-B2 | Green synthesis of aryl aldimines using ethyl lactate | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2014-07-01 | — | — | US | disclosed |
| US-8569346-B1 | Thiazoline ring compounds as botulinum antagonists | BIOMADISON, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20110196174-A1 | GREEN SYNTHESIS OF ARYL ALDIMINES USING ETHYL LACTATE | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2011-08-11 | — | — | US | disclosed |
| US-20110172234-A1 | METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110172234-A1 | METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-07-14 | — | — | US | disclosed |
| US-7915245-B2 | Using small molecules as binding ligands, for the recruitment of Fas-associated death domain protein, activation of death-inducing signaling complex, caspase-8, and apoptosis in malignant cells; anticarcinogens, antitumor agents; enhanced cellular differentiation, minimizing cytolysis to healthy cells | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-03-29 | — | — | US | disclosed |
| US-7915245-B2 | Using small molecules as binding ligands, for the recruitment of Fas-associated death domain protein, activation of death-inducing signaling complex, caspase-8, and apoptosis in malignant cells; anticarcinogens, antitumor agents; enhanced cellular differentiation, minimizing cytolysis to healthy cells | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-03-29 | — | — | US | disclosed |
| US-20080214547-A1 | METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS | UNIVERSITY OF MARYLAND, BALTIMORE | 2008-09-04 | — | — | US | disclosed |
| EP-1120248-A2 | Printing plate and method for its preparation | Kodak Polychrome Graphics Company Ltd. (US) | 2001-08-01 | — | — | EP | disclosed |
| US-5082938-A | Having a high density hydroxyl distribution and branching due to a glycidol component; improved compatibility in polymer substrates; polyurethane intermediates; amine functionalities | MILLIKEN RESEARCH CORPORATION (US) | 1992-01-21 | — | — | US | disclosed |
| US-4235929-A | TOPICAL ADMINISTRATION OF ANTIINFLAMMATORY AGENT | WILLIAM H. RORER, INC. (US) | 1980-11-25 | — | — | US | disclosed |
| US-4224340-A | Anti-inflammatory compositions containing α-phenyl-N-phenylnitrone compounds | WILLIAM H. RORER, INC. (US) | 1980-09-23 | — | — | US | disclosed |
| US-4214003-A | ANTIINFLAMMATORY AGENTS | WILLIAM H. RORER, INC. (US) | 1980-07-22 | — | — | US | disclosed |
| US-4214094-A | ANTILIPEMIC AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-07-22 | — | — | US | disclosed |
| US-4198349-A | ANTIINFLAMMATORY, TOPICAL | WILLIAM H. RORER, INC. (US) | 1980-04-15 | — | — | US | disclosed |
| US-4197314-A | WITH A DIPHENYL NITRONE | WILLIAM H. RORER, INC. (US) | 1980-04-08 | — | — | US | disclosed |
| US-4176198-A | ANTIINFLAMMATORY AGENTS | WILLIAM H. RORER, INC. (US) | 1979-11-27 | — | — | US | disclosed |
| US-4153722-A | ANTIINFLAMMATORY, A-PHENYL-N-PHENYLNITRONE | WILLIAM H. RORER, INC. (US) | 1979-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214547-A1 | METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS | BID, BAD, MCL1 | S100B 4126/4885CA2 2958/4885ALDH1A1 3768/4885 |
| US-20110196174-A1 | GREEN SYNTHESIS OF ARYL ALDIMINES USING ETHYL LACTATE | LDHA, LDHB, ALDOA | S100B 2421/4885CA2 1478/4885ALDH1A1 18/4885 |
| US-20110172234-A1 | METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS | BID, BAD, MCL1 | S100B 4126/4885CA2 2958/4885ALDH1A1 3768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.